Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клиническое значение определения антител к тромбоспондину 1-го типа, содержащему домен 7А (THSD7A), при мембранозной нефропатии
Клиническое значение определения антител к тромбоспондину 1-го типа, содержащему домен 7А (THSD7A), при мембранозной нефропатии
Кахсуруева П.А., Камышова Е.С., Бобкова И.Н., Ставровская Е.В., Руденко Т.Е., Андреева Е.Ю. Клиническое значение определения антител к тромбоспондину 1-го типа, содержащему домен 7А (THSD7A), при мембранозной нефропатии. Терапевтический архив. 2023;95(6):462–467.
DOI: 10.26442/00403660.2023.06.202268
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/00403660.2023.06.202268
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обоснование. Мембранозная нефропатия (МН) – иммунокомплексное гломерулярное заболевание, которое является наиболее частой причиной нефротического синдрома у взрослых. В многочисленных исследованиях установлено, что в развитии идиопатической МН ведущую роль играют антитела к собственным подоцитарным аутоантигенам, одним из которых является домен тромбоспондина 1-го типа, содержащий 7А (THSD7A).
Цель. Изучить частоту выявления антител (АТ) к THSD7A в группе российских пациентов с МН.
Материалы и методы. У 61 пациента с морфологически подтвержденной МН и 12 здоровых добровольцев, составивших контрольную группу, определены уровни АТ к THSD7A.
Результаты. Уровни АТ к THSD7A у пациентов с МН и в контрольной группе статистически значимо не различались (110,9 [71,63; 210,62] и 159,25 [125,64; 231,97] пг/мл соответственно; p=0,111). При сравнении подгрупп анти-PLA2R-негативных пациентов и пациентов, не получавших иммуносупрессивную терапию, с контрольной группой статистически значимых различий в уровнях АТ к THSD7A также не выявлено (p>0,05). В группе МН анти-THSD7A-позитивным оказался 1 (1,6%) пациент – 60-летний мужчина с анти-PLA2R-негативной МН и наличием гормонально неактивных аденом обоих надпочечников и полипов толстой кишки (ворсинчатая аденома с очаговой умеренной дисплазией, тубуло-ворсинчатая и тубулярная аденома с очаговой умеренно тяжелой дисплазией).
Заключение. THSD7-ассоциированная МН является редким вариантом МН и, как правило, выявляется у PLA2R-негативных пациентов. Всем THSD7A-позитивным пациентам следует проводить скрининг злокачественных новообразований.
Ключевые слова: мембранозная нефропатия, домен тромбоспондина 1-го типа, содержащий 7А, THSD7A, рецептор фосфолипазы А2 М-типа, PLA2R
Aim. To evaluate the prevalence of anti-THSD7A autoantibodies (anti-THSD7A AB) in a group of Russian patients with MN.
Materials and methods. Serum titers of anti-THSD7A AB were tested in 61 patients with biopsy-proven MN and 12 healthy controls.
Results. The prevalence of anti-THSD7A AB was not differing significantly in patients with MN and in the control group (110.9 [71.63; 210.62] and 159.25 [125.64; 231.97] pg/ml, respectively; p=0.111). When comparing subgroups of anti-PLA2R-negative patients and patients who did not receive immunosuppressive therapy with the control group, there were also no statistically significant differences in the Anti-THSD7A AB levels (p>0.05). In the MN group, 1 (1.6%) patient was anti-THSD7A-positive: a 60-year-old man with anti-PLA2R-negative MN and the presence of hormonally inactive adenomas of both adrenal glands and colon polyps (villous adenoma with focal moderate dysplasia, tubulo-villous and tubular adenoma with focal moderate severe dysplasia).
Conclusion. THSD7-associated MN is a rare variant of MN and is usually detected in PLA2R-negative patients. Screening for malignancies in THSD7A-positive MN patients is proposed.
Keywords: membranous nephropathy, thrombospondin type 1 domain-containing 7A, THSD7A, M-type phospholipase A2 receptor, PLA2R
Цель. Изучить частоту выявления антител (АТ) к THSD7A в группе российских пациентов с МН.
Материалы и методы. У 61 пациента с морфологически подтвержденной МН и 12 здоровых добровольцев, составивших контрольную группу, определены уровни АТ к THSD7A.
Результаты. Уровни АТ к THSD7A у пациентов с МН и в контрольной группе статистически значимо не различались (110,9 [71,63; 210,62] и 159,25 [125,64; 231,97] пг/мл соответственно; p=0,111). При сравнении подгрупп анти-PLA2R-негативных пациентов и пациентов, не получавших иммуносупрессивную терапию, с контрольной группой статистически значимых различий в уровнях АТ к THSD7A также не выявлено (p>0,05). В группе МН анти-THSD7A-позитивным оказался 1 (1,6%) пациент – 60-летний мужчина с анти-PLA2R-негативной МН и наличием гормонально неактивных аденом обоих надпочечников и полипов толстой кишки (ворсинчатая аденома с очаговой умеренной дисплазией, тубуло-ворсинчатая и тубулярная аденома с очаговой умеренно тяжелой дисплазией).
Заключение. THSD7-ассоциированная МН является редким вариантом МН и, как правило, выявляется у PLA2R-негативных пациентов. Всем THSD7A-позитивным пациентам следует проводить скрининг злокачественных новообразований.
Ключевые слова: мембранозная нефропатия, домен тромбоспондина 1-го типа, содержащий 7А, THSD7A, рецептор фосфолипазы А2 М-типа, PLA2R
________________________________________________
Aim. To evaluate the prevalence of anti-THSD7A autoantibodies (anti-THSD7A AB) in a group of Russian patients with MN.
Materials and methods. Serum titers of anti-THSD7A AB were tested in 61 patients with biopsy-proven MN and 12 healthy controls.
Results. The prevalence of anti-THSD7A AB was not differing significantly in patients with MN and in the control group (110.9 [71.63; 210.62] and 159.25 [125.64; 231.97] pg/ml, respectively; p=0.111). When comparing subgroups of anti-PLA2R-negative patients and patients who did not receive immunosuppressive therapy with the control group, there were also no statistically significant differences in the Anti-THSD7A AB levels (p>0.05). In the MN group, 1 (1.6%) patient was anti-THSD7A-positive: a 60-year-old man with anti-PLA2R-negative MN and the presence of hormonally inactive adenomas of both adrenal glands and colon polyps (villous adenoma with focal moderate dysplasia, tubulo-villous and tubular adenoma with focal moderate severe dysplasia).
Conclusion. THSD7-associated MN is a rare variant of MN and is usually detected in PLA2R-negative patients. Screening for malignancies in THSD7A-positive MN patients is proposed.
Keywords: membranous nephropathy, thrombospondin type 1 domain-containing 7A, THSD7A, M-type phospholipase A2 receptor, PLA2R
Полный текст
Список литературы
1. Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346(26):2053-60. DOI:10.1056/NEJMoa012895
2. Madaio MP, Salant DJ, Cohen AJ, et al. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int. 1983;23(3):498-505. DOI:10.1038/ki.1983.47
3. Beck LH Jr., Bonegio RG, Lambeau G, et al. M-Type Phospholipase A2 Receptor as Target Antigen in IdiopathicMembranous Nephropathy. N Engl J Med. 2009;361(1):11-21. DOI:10.1056/NEJMoa0810457
4. Qin W, Beck LH Jr., Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-43. DOI:10.1681/ASN.2010090967
5. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-32. DOI:10.1093/ndt/gfr247
6. Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol.
2015;19(4):653-60. DOI:10.1007/s10157-014-1054-2
7. Hayashi N, Akiyama S, Okuyama H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19(5):797-803. DOI:10.1007/s10157-014-1064-0
8. Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype. Virchows Arch. 2015;467(1):87-94. DOI:10.1007/s00428-015-1754-3
9. Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-38. DOI:10.1016/j.kint.2018.10.021
10. De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421-30. DOI:10.1681/ASN.2016070776
11. Hofstra JM, Beck LH Jr., Beck DM, et al. Anti-Phospholipase A(2) Receptor Antibodies Correlate With Clinical Status in Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-91. DOI:10.2215/CJN.07210810
12. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386-92. DOI:10.2215/CJN.10471013
13. Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58. DOI:10.1681/ASN.2014070640
14. Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients With Idiopathic Membranous Nephropathy. Kidney Int. 2013;83(5):940-8. DOI:10.1038/ki.2012.486
15. Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. Transplantation. 2015;99(8):1709-14. DOI:10.1097/TP.0000000000000630
16. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, et al. Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. N Engl J Med. 2014;371(24):2277-87. DOI:10.1056/NEJMoa1409354
17. Hoxha E, Beck LH Jr., Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):520-31. DOI:10.1681/ASN.2016010050
18. Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642‑51. DOI:10.2215/CJN.01460217
19. Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016;126(7):2519-32.
DOI:10.1172/JCI85265
20. Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. J Am Soc Nephrol. 2017;28(11):3262-77. DOI:10.1681/ASN.2017010030
21. Hoxha E, Wiech T, Stahl PR, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016;374(20):1995-6. DOI:10.1056/NEJMc1511702
22. Liu Y, Zheng S, Ma C, et al. Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy. Glob Chall. 2020;4(11):1900099. DOI:10.1002/gch2.201900099
23. Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666-79. DOI:10.1016/j.kint.2018.10.024
24. Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-22. DOI:10.1038/modpathol.2017.163
25. Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735-43. DOI:10.1007/s00428-019-02558-0
26. Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-13. DOI:10.1080/0886022X.2018.1456457
27. Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29-35. DOI:10.1159/000364782
2. Madaio MP, Salant DJ, Cohen AJ, et al. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int. 1983;23(3):498-505. DOI:10.1038/ki.1983.47
3. Beck LH Jr., Bonegio RG, Lambeau G, et al. M-Type Phospholipase A2 Receptor as Target Antigen in IdiopathicMembranous Nephropathy. N Engl J Med. 2009;361(1):11-21. DOI:10.1056/NEJMoa0810457
4. Qin W, Beck LH Jr., Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-43. DOI:10.1681/ASN.2010090967
5. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-32. DOI:10.1093/ndt/gfr247
6. Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol.
2015;19(4):653-60. DOI:10.1007/s10157-014-1054-2
7. Hayashi N, Akiyama S, Okuyama H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19(5):797-803. DOI:10.1007/s10157-014-1064-0
8. Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype. Virchows Arch. 2015;467(1):87-94. DOI:10.1007/s00428-015-1754-3
9. Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-38. DOI:10.1016/j.kint.2018.10.021
10. De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421-30. DOI:10.1681/ASN.2016070776
11. Hofstra JM, Beck LH Jr., Beck DM, et al. Anti-Phospholipase A(2) Receptor Antibodies Correlate With Clinical Status in Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-91. DOI:10.2215/CJN.07210810
12. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386-92. DOI:10.2215/CJN.10471013
13. Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58. DOI:10.1681/ASN.2014070640
14. Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients With Idiopathic Membranous Nephropathy. Kidney Int. 2013;83(5):940-8. DOI:10.1038/ki.2012.486
15. Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. Transplantation. 2015;99(8):1709-14. DOI:10.1097/TP.0000000000000630
16. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, et al. Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. N Engl J Med. 2014;371(24):2277-87. DOI:10.1056/NEJMoa1409354
17. Hoxha E, Beck LH Jr., Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):520-31. DOI:10.1681/ASN.2016010050
18. Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642‑51. DOI:10.2215/CJN.01460217
19. Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016;126(7):2519-32.
DOI:10.1172/JCI85265
20. Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. J Am Soc Nephrol. 2017;28(11):3262-77. DOI:10.1681/ASN.2017010030
21. Hoxha E, Wiech T, Stahl PR, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016;374(20):1995-6. DOI:10.1056/NEJMc1511702
22. Liu Y, Zheng S, Ma C, et al. Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy. Glob Chall. 2020;4(11):1900099. DOI:10.1002/gch2.201900099
23. Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666-79. DOI:10.1016/j.kint.2018.10.024
24. Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-22. DOI:10.1038/modpathol.2017.163
25. Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735-43. DOI:10.1007/s00428-019-02558-0
26. Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-13. DOI:10.1080/0886022X.2018.1456457
27. Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29-35. DOI:10.1159/000364782
2. Madaio MP, Salant DJ, Cohen AJ, et al. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int. 1983;23(3):498-505. DOI:10.1038/ki.1983.47
3. Beck LH Jr., Bonegio RG, Lambeau G, et al. M-Type Phospholipase A2 Receptor as Target Antigen in IdiopathicMembranous Nephropathy. N Engl J Med. 2009;361(1):11-21. DOI:10.1056/NEJMoa0810457
4. Qin W, Beck LH Jr., Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-43. DOI:10.1681/ASN.2010090967
5. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-32. DOI:10.1093/ndt/gfr247
6. Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol.
2015;19(4):653-60. DOI:10.1007/s10157-014-1054-2
7. Hayashi N, Akiyama S, Okuyama H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19(5):797-803. DOI:10.1007/s10157-014-1064-0
8. Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype. Virchows Arch. 2015;467(1):87-94. DOI:10.1007/s00428-015-1754-3
9. Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-38. DOI:10.1016/j.kint.2018.10.021
10. De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421-30. DOI:10.1681/ASN.2016070776
11. Hofstra JM, Beck LH Jr., Beck DM, et al. Anti-Phospholipase A(2) Receptor Antibodies Correlate With Clinical Status in Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-91. DOI:10.2215/CJN.07210810
12. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386-92. DOI:10.2215/CJN.10471013
13. Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58. DOI:10.1681/ASN.2014070640
14. Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients With Idiopathic Membranous Nephropathy. Kidney Int. 2013;83(5):940-8. DOI:10.1038/ki.2012.486
15. Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. Transplantation. 2015;99(8):1709-14. DOI:10.1097/TP.0000000000000630
16. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, et al. Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. N Engl J Med. 2014;371(24):2277-87. DOI:10.1056/NEJMoa1409354
17. Hoxha E, Beck LH Jr., Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):520-31. DOI:10.1681/ASN.2016010050
18. Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642‑51. DOI:10.2215/CJN.01460217
19. Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016;126(7):2519-32.
DOI:10.1172/JCI85265
20. Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. J Am Soc Nephrol. 2017;28(11):3262-77. DOI:10.1681/ASN.2017010030
21. Hoxha E, Wiech T, Stahl PR, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016;374(20):1995-6. DOI:10.1056/NEJMc1511702
22. Liu Y, Zheng S, Ma C, et al. Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy. Glob Chall. 2020;4(11):1900099. DOI:10.1002/gch2.201900099
23. Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666-79. DOI:10.1016/j.kint.2018.10.024
24. Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-22. DOI:10.1038/modpathol.2017.163
25. Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735-43. DOI:10.1007/s00428-019-02558-0
26. Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-13. DOI:10.1080/0886022X.2018.1456457
27. Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29-35. DOI:10.1159/000364782
________________________________________________
2. Madaio MP, Salant DJ, Cohen AJ, et al. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int. 1983;23(3):498-505. DOI:10.1038/ki.1983.47
3. Beck LH Jr., Bonegio RG, Lambeau G, et al. M-Type Phospholipase A2 Receptor as Target Antigen in IdiopathicMembranous Nephropathy. N Engl J Med. 2009;361(1):11-21. DOI:10.1056/NEJMoa0810457
4. Qin W, Beck LH Jr., Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-43. DOI:10.1681/ASN.2010090967
5. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-32. DOI:10.1093/ndt/gfr247
6. Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol.
2015;19(4):653-60. DOI:10.1007/s10157-014-1054-2
7. Hayashi N, Akiyama S, Okuyama H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19(5):797-803. DOI:10.1007/s10157-014-1064-0
8. Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype. Virchows Arch. 2015;467(1):87-94. DOI:10.1007/s00428-015-1754-3
9. Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-38. DOI:10.1016/j.kint.2018.10.021
10. De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421-30. DOI:10.1681/ASN.2016070776
11. Hofstra JM, Beck LH Jr., Beck DM, et al. Anti-Phospholipase A(2) Receptor Antibodies Correlate With Clinical Status in Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-91. DOI:10.2215/CJN.07210810
12. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386-92. DOI:10.2215/CJN.10471013
13. Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58. DOI:10.1681/ASN.2014070640
14. Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients With Idiopathic Membranous Nephropathy. Kidney Int. 2013;83(5):940-8. DOI:10.1038/ki.2012.486
15. Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. Transplantation. 2015;99(8):1709-14. DOI:10.1097/TP.0000000000000630
16. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, et al. Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. N Engl J Med. 2014;371(24):2277-87. DOI:10.1056/NEJMoa1409354
17. Hoxha E, Beck LH Jr., Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):520-31. DOI:10.1681/ASN.2016010050
18. Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642‑51. DOI:10.2215/CJN.01460217
19. Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016;126(7):2519-32.
DOI:10.1172/JCI85265
20. Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. J Am Soc Nephrol. 2017;28(11):3262-77. DOI:10.1681/ASN.2017010030
21. Hoxha E, Wiech T, Stahl PR, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016;374(20):1995-6. DOI:10.1056/NEJMc1511702
22. Liu Y, Zheng S, Ma C, et al. Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy. Glob Chall. 2020;4(11):1900099. DOI:10.1002/gch2.201900099
23. Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666-79. DOI:10.1016/j.kint.2018.10.024
24. Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-22. DOI:10.1038/modpathol.2017.163
25. Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735-43. DOI:10.1007/s00428-019-02558-0
26. Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-13. DOI:10.1080/0886022X.2018.1456457
27. Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29-35. DOI:10.1159/000364782
Авторы
П.А. Кахсуруева, Е.С. Камышова*, И.Н. Бобкова, Е.В. Ставровская, Т.Е. Руденко, Е.Ю. Андреева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*kamyshova_e_s@staff.sechenov.ru
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*kamyshova_e_s@staff.sechenov.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*kamyshova_e_s@staff.sechenov.ru
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*kamyshova_e_s@staff.sechenov.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.